Skip to content
Not evaluated by SAHPRA · Research & educational information only · Nothing on this site is for sale · Not medical advice · Consult a healthcare professional
Not evaluated by SAHPRA. Research & educational information only — nothing is for sale; not intended to diagnose, treat, cure or prevent any disease.
← Back to catalogue
Weight LossPeptide vialTriple agonistResearchWeight Loss

UPA Retatrutide

Triple agonist. The most-studied next-wave weight-loss peptide.

Format
Peptide vial
Strength / pack
30 mg vial
Category
Weight Loss
Triple mechanismActivates GIP, GLP-1 and glucagon receptors simultaneously.
Highest trial resultsPhase 2 trials reported the largest weight reductions to date in class.
Metabolic upgradeGlucagon arm increases energy expenditure in addition to appetite control.
Full-spectrum supportImproves glucose, lipids, and liver fat markers.
Retatrutide adds glucagon-receptor activation on top of the dual GIP/GLP-1 mechanism. Glucagon at these levels increases basal metabolic rate and hepatic fat oxidation — complementing appetite suppression with real energy expenditure.
Publisher
Elegant Slimming · Mokopane, Limpopo, South Africa
Research library · nothing on this site is for sale.
Regulatory
This compound has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.